Mario Giorgio Rizzone
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mario Giorgio Rizzone has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
Leonardo Lopiano
Department of Neuroscience “Rita Levi Montalcini” University of Torino Turin Italy
5 shared publications- Maurizio Zibetti
Department of Neuroscience “Rita Levi Montalcini” University of Turin Turin Italy
5 shared publications Alberto Romagnolo
Department of Neuroscience “Rita Levi Montalcini” University of Torino Turin Italy
3 shared publications- Leonardo Lopiano
Department of Neuroscience “Rita Levi Montalcini”, University of Turin, 10126 Turin, Italy
3 shared publications - Alberto Romagnolo
Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy
2 shared publications - Carla Piano
Department of Neuroscience, Università Cattolica del Sacro Cuore, Rome, Italy; and
2 shared publications
Latest Publications
- Open Access
- 5 May 2025
- Published by Wiley in Movement Disorders
- Vol. 40 (6) , 1189-1194
Theta‐Gamma Subthalamic Stimulation for Verbal Fluency in Parkinson's Disease: A Randomized, Crossover Trial
Background: High‐frequency deep brain stimulation (DBS) of the subthalamic nucleus (STN) improves Parkinson's disease (PD) motor symptoms but may deteriorate verbal fluency (VF). Theta stimulation showed potential cognitive benefits associated with motor worsening.Objectives: This randomized, double‐blind, crossover study evaluated the efficacy and safety of combined theta‐gamma frequency stimulation on VF in PD patients with STN‐DBS.Methods: Patients were randomized 1:1 for standard or theta‐gamma stimulation. VF, motor, and non‐motor symptoms were assessed at baseline, 1 h, and 1 month after each period. Data were analyzed using a linear mixed‐effects model.Results: Twelve patients completed the study. Non‐episodic (P = 0.038) and episodic VF (P = 0.030) improved after 1 month of theta‐gamma stimulation, while phonemic and switching fluency were unchanged. Motor and non‐motor outcomes were unaffected by the stimulation, with mild adverse events.Conclusion: Combined theta‐gamma stimulation may enhance VF in PD patients with STN‐DBS without worsening motor symptoms or safety concerns. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- 5 May 2025
- Published by Wiley in Movement Disorders
- Vol. 40 (6) , 1189-1194
Open AccessTheta‐Gamma Subthalamic Stimulation for Verbal Fluency in Parkinson's Disease: A Randomized, Crossover Trial
Background: High‐frequency deep brain stimulation (DBS) of the subthalamic nucleus (STN) improves Parkinson's disease (PD) motor symptoms but may deteriorate verbal fluency (VF). Theta stimulation showed potential cognitive benefits associated with motor worsening.Objectives: This randomized, double‐blind, crossover study evaluated the efficacy and safety of combined theta‐gamma frequency stimulation on VF in PD patients with STN‐DBS.Methods: Patients were randomized 1:1 for standard or theta‐gamma stimulation. VF, motor, and non‐motor symptoms were assessed at baseline, 1 h, and 1 month after each period. Data were analyzed using a linear mixed‐effects model.Results: Twelve patients completed the study. Non‐episodic (P = 0.038) and episodic VF (P = 0.030) improved after 1 month of theta‐gamma stimulation, while phonemic and switching fluency were unchanged. Motor and non‐motor outcomes were unaffected by the stimulation, with mild adverse events.Conclusion: Combined theta‐gamma stimulation may enhance VF in PD patients with STN‐DBS without worsening motor symptoms or safety concerns. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- Open Access
- 1 December 2024
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 14 (8) , 1602-1613
Subthalamic and nigral stimulation for freezing of gait in Parkinson's disease: Randomized pilot trial
Background: Freezing of gait (FoG) is a debilitating symptom of Parkinson's disease (PD) with limited response to dopaminergic medication and subthalamic deep brain stimulation (STN-DBS). Substantia nigra pars reticulata (SNr) stimulation could improve FoG. Objective: To analyze the effect of combined STN-SNr stimulation at different frequencies on FoG. Methods: We performed a double-blind, cross-over, randomized pilot trial involving STN-DBS treated PD patients with FoG. Participants received: high-frequency (HF) STN-DBS (S), combined HF-STN and SNr stimulation (C1), and combined HF-STN and low-frequency (LF) SNr stimulation (C2), for one month each. The primary endpoint was the score change in the New-Freezing-of-Gait-Questionnaire (NFOG-Q). Secondary analyses were performed on motor complications, axial symptoms, daily living activities, psychiatric symptoms, sleep, and patient preference. Results: Fifteen patients received at least one combined stimulation. No significant difference in NFOG-Q scores was found between S, C1, and C2; one-third of patients showed a clinically significant improvement (≥8 points) with combined stimulations. Motor complications improved significantly with C1 and C2 (C1-S: 3.6 ± 3.8 vs. 4.9 ± 3.8, p = 0.046; C2-S: 2.7 ± 3.1 vs. 4.9 ± 3.8, p = 0.005). 80% of patients preferred the combined STN-SNr stimulation while blinded. All adverse events were manageable. Conclusions: Our study did not prove a statistically significant improvement in NFOG-Q with STN-SNr stimulation; however, one-third of patients experienced a clinically meaningful FoG improvement, and the majority preferred to maintain STN-SNr stimulation. STN-SNr stimulation was both safe and effective in addressing motor complications and improving sleep quality, highlighting the importance of further exploration into the effects of combined STN-SNr stimulation.
- 1 December 2024
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 14 (8) , 1602-1613
Open AccessSubthalamic and nigral stimulation for freezing of gait in Parkinson's disease: Randomized pilot trial
Background: Freezing of gait (FoG) is a debilitating symptom of Parkinson's disease (PD) with limited response to dopaminergic medication and subthalamic deep brain stimulation (STN-DBS). Substantia nigra pars reticulata (SNr) stimulation could improve FoG. Objective: To analyze the effect of combined STN-SNr stimulation at different frequencies on FoG. Methods: We performed a double-blind, cross-over, randomized pilot trial involving STN-DBS treated PD patients with FoG. Participants received: high-frequency (HF) STN-DBS (S), combined HF-STN and SNr stimulation (C1), and combined HF-STN and low-frequency (LF) SNr stimulation (C2), for one month each. The primary endpoint was the score change in the New-Freezing-of-Gait-Questionnaire (NFOG-Q). Secondary analyses were performed on motor complications, axial symptoms, daily living activities, psychiatric symptoms, sleep, and patient preference. Results: Fifteen patients received at least one combined stimulation. No significant difference in NFOG-Q scores was found between S, C1, and C2; one-third of patients showed a clinically significant improvement (≥8 points) with combined stimulations. Motor complications improved significantly with C1 and C2 (C1-S: 3.6 ± 3.8 vs. 4.9 ± 3.8, p = 0.046; C2-S: 2.7 ± 3.1 vs. 4.9 ± 3.8, p = 0.005). 80% of patients preferred the combined STN-SNr stimulation while blinded. All adverse events were manageable. Conclusions: Our study did not prove a statistically significant improvement in NFOG-Q with STN-SNr stimulation; however, one-third of patients experienced a clinically meaningful FoG improvement, and the majority preferred to maintain STN-SNr stimulation. STN-SNr stimulation was both safe and effective in addressing motor complications and improving sleep quality, highlighting the importance of further exploration into the effects of combined STN-SNr stimulation.
- Open Access
- 30 May 2022
- Published by Wiley in European Journal of Neurology
- Vol. 29 (8) , 2211-2219
Social cognition deficits in amyotrophic lateral sclerosis: A pilot cross‐sectional population‐based study
Background and purpose: Social cognition (SC) deficits are included in amyotrophic lateral sclerosis (ALS)–frontotemporal spectrum disorder revised diagnostic criteria. However, SC performance among ALS patients is heterogeneous due to the phenotypic variability of the disease and the wide range of neuropsychological tools employed. The aim of the present study was to assess facial emotion recognition and theory of mind in ALS patients compared to controls and to evaluate correlations with the other cognitive domains and degree of motor impairment.Methods: Eighty‐three patients and 42 controls underwent a cognitive evaluation and SC assessment through the Ekman 60 Faces Test (EK‐60F), the Reading the Mind in the Eyes Test–36 Faces (RMET‐36), and the Story‐Based Empathy Task (SET).Results: ALS patients showed significantly worse performance compared to controls in EK‐60F global score (p < 0.001), recognition of disgust (p = 0.032), anger (p = 0.038), fear (p < 0.001), and sadness (p < 0.001); RMET‐36 (p < 0.001), and SET global score (p < 0.001). Also, cognitively normal patients (ALS‐CN) showed significantly worse performance compared to controls in EK‐60F global score (p < 0.001), recognition of fear (p = 0.002), sadness (p < 0.001), and SET (p < 0.001). RMET‐36 showed a significant correlation with the Category Fluency Test (p = 0.041). SC tests showed no correlation with motor impairment expressed by Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised.Conclusions: ALS patients, also when categorized as ALS‐CN, may show impairment in SC performance. The frequent identification of early SC impairment in ALS patients supports the need to routinely assess SC for its impact on end‐of‐life decisions and its potential influence on patients' quality of life.
- 30 May 2022
- Published by Wiley in European Journal of Neurology
- Vol. 29 (8) , 2211-2219
Open AccessSocial cognition deficits in amyotrophic lateral sclerosis: A pilot cross‐sectional population‐based study
Background and purpose: Social cognition (SC) deficits are included in amyotrophic lateral sclerosis (ALS)–frontotemporal spectrum disorder revised diagnostic criteria. However, SC performance among ALS patients is heterogeneous due to the phenotypic variability of the disease and the wide range of neuropsychological tools employed. The aim of the present study was to assess facial emotion recognition and theory of mind in ALS patients compared to controls and to evaluate correlations with the other cognitive domains and degree of motor impairment.Methods: Eighty‐three patients and 42 controls underwent a cognitive evaluation and SC assessment through the Ekman 60 Faces Test (EK‐60F), the Reading the Mind in the Eyes Test–36 Faces (RMET‐36), and the Story‐Based Empathy Task (SET).Results: ALS patients showed significantly worse performance compared to controls in EK‐60F global score (p < 0.001), recognition of disgust (p = 0.032), anger (p = 0.038), fear (p < 0.001), and sadness (p < 0.001); RMET‐36 (p < 0.001), and SET global score (p < 0.001). Also, cognitively normal patients (ALS‐CN) showed significantly worse performance compared to controls in EK‐60F global score (p < 0.001), recognition of fear (p = 0.002), sadness (p < 0.001), and SET (p < 0.001). RMET‐36 showed a significant correlation with the Category Fluency Test (p = 0.041). SC tests showed no correlation with motor impairment expressed by Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised.Conclusions: ALS patients, also when categorized as ALS‐CN, may show impairment in SC performance. The frequent identification of early SC impairment in ALS patients supports the need to routinely assess SC for its impact on end‐of‐life decisions and its potential influence on patients' quality of life.
- 4 January 2022
- Published by Springer Nature in Neurological Sciences
- Vol. 43 (5) , 3187-3193
Efficacy of safinamide as add-on therapy after subthalamic nucleus deep brain stimulation in Parkinson disease
Background Subthalamic nucleus deep brain stimulation (STN-DBS) is an effective surgical treatment for advanced Parkinson’s disease (PD). However, some patients still experience motor fluctuations or dyskinesia after STN-DBS. Safinamide is approved as add-on treatment to levodopa in fluctuating PD patients. In this study, we evaluated the effect of safinamide as adjunctive therapy in PD patients still experiencing motor fluctuations and dyskinesias after STN-DBS. Methods PD patients treated for at least 2 years with bilateral STN-DBST and with troublesome motor fluctuation and/or dyskinesias were examined by means of the Movement Disorders Society—Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), the quality of life questionnaire Parkinson’s Disease Questionnaire-8 (PDQ-8) and the Non-Motor Symptoms Scale (NMSS) at baseline (T0), after 1 month of treatment with safinamide 50 mg daily (T1) and after another month of treatment with safinamide 100 mg daily (T2). Results Twenty-nine PD patients were examined. An improvement of the MDS-UPDRS IV score (motor complications) was observed between T0 and T1, T0 and T2, and T1 and T2. The time spent in the OFF state, the functional impact and the complexity of motor fluctuations significantly improved between T0 and T1 and T0 and T2. The mean levodopa equivalent daily dose significantly decreased from T0 to T1 and from T0 to T2. Regarding non-motor symptoms, an improvement on mood and pain was observed. Conclusions Safinamide seems to be an effective adjunctive treatment in PD patients treated with bilateral STN-DBS, leading to an improvement of motor complications, mood and pain.
- 4 January 2022
- Published by Springer Nature in Neurological Sciences
- Vol. 43 (5) , 3187-3193
Efficacy of safinamide as add-on therapy after subthalamic nucleus deep brain stimulation in Parkinson disease
Background Subthalamic nucleus deep brain stimulation (STN-DBS) is an effective surgical treatment for advanced Parkinson’s disease (PD). However, some patients still experience motor fluctuations or dyskinesia after STN-DBS. Safinamide is approved as add-on treatment to levodopa in fluctuating PD patients. In this study, we evaluated the effect of safinamide as adjunctive therapy in PD patients still experiencing motor fluctuations and dyskinesias after STN-DBS. Methods PD patients treated for at least 2 years with bilateral STN-DBST and with troublesome motor fluctuation and/or dyskinesias were examined by means of the Movement Disorders Society—Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), the quality of life questionnaire Parkinson’s Disease Questionnaire-8 (PDQ-8) and the Non-Motor Symptoms Scale (NMSS) at baseline (T0), after 1 month of treatment with safinamide 50 mg daily (T1) and after another month of treatment with safinamide 100 mg daily (T2). Results Twenty-nine PD patients were examined. An improvement of the MDS-UPDRS IV score (motor complications) was observed between T0 and T1, T0 and T2, and T1 and T2. The time spent in the OFF state, the functional impact and the complexity of motor fluctuations significantly improved between T0 and T1 and T0 and T2. The mean levodopa equivalent daily dose significantly decreased from T0 to T1 and from T0 to T2. Regarding non-motor symptoms, an improvement on mood and pain was observed. Conclusions Safinamide seems to be an effective adjunctive treatment in PD patients treated with bilateral STN-DBS, leading to an improvement of motor complications, mood and pain.
- 25 May 2020
- Published by Wiley in Movement Disorders
- Vol. 35 (8) , 1379-1387
Should We Consider Deep Brain Stimulation Discontinuation in Late‐Stage Parkinson's Disease?
Background: Subthalamic deep brain stimulation (STN‐DBS) effects may decrease with Parkinson's disease (PD) progression. There is no indication if, when, and how to consider the interruption of DBS treatment in late‐stage PD. The objective of the current study was to investigate the percentage of “poor stimulation responders” among late‐stage PD patients for elaborating an algorithm to decide whether and when DBS discontinuation may be considered.Methods: Late‐stage PD patients (Hoehn Yahr stage ≥4 and Schwab and England Scale <50 in medication on/stimulation on condition) treated with STN‐DBS for at least 5 years underwent a crossover, double‐blind, randomized evaluation of acute effects of stimulation. Physicians, caregivers, and patients were blinded to stimulation conditions. Poor stimulation responders (MDS‐UPDRS part III change <10% between stimulation on/medication off and stimulation off/medication off) maintained the stimulation off/medication on condition for 1 month for open‐label assessment.Results: Thirty‐six patients were included. The acute effect of stimulation was significant (17% MDS‐UPDRS part III), with 80% of patients classified as “good responders.” Seven patients were classified as “poor stimulation responders,” and the stimulation was switched off, but in 4 cases the stimulation was switched back “on” because of worsening of parkinsonism and dysphagia with a variable time delay (up to 10 days). No serious adverse effects occurred.Conclusions: The vast majority of late‐stage PD patients (92%) show a meaningful response to STN‐DBS. Effects of stimulation may take days to disappear after its discontinuation. We present a safe and effective decisional algorithm that could guide physicians and caregivers in making challenging therapeutic decisions in late‐stage PD. © 2020 International Parkinson and Movement Disorder Society
- 25 May 2020
- Published by Wiley in Movement Disorders
- Vol. 35 (8) , 1379-1387
Should We Consider Deep Brain Stimulation Discontinuation in Late‐Stage Parkinson's Disease?
Background: Subthalamic deep brain stimulation (STN‐DBS) effects may decrease with Parkinson's disease (PD) progression. There is no indication if, when, and how to consider the interruption of DBS treatment in late‐stage PD. The objective of the current study was to investigate the percentage of “poor stimulation responders” among late‐stage PD patients for elaborating an algorithm to decide whether and when DBS discontinuation may be considered.Methods: Late‐stage PD patients (Hoehn Yahr stage ≥4 and Schwab and England Scale <50 in medication on/stimulation on condition) treated with STN‐DBS for at least 5 years underwent a crossover, double‐blind, randomized evaluation of acute effects of stimulation. Physicians, caregivers, and patients were blinded to stimulation conditions. Poor stimulation responders (MDS‐UPDRS part III change <10% between stimulation on/medication off and stimulation off/medication off) maintained the stimulation off/medication on condition for 1 month for open‐label assessment.Results: Thirty‐six patients were included. The acute effect of stimulation was significant (17% MDS‐UPDRS part III), with 80% of patients classified as “good responders.” Seven patients were classified as “poor stimulation responders,” and the stimulation was switched off, but in 4 cases the stimulation was switched back “on” because of worsening of parkinsonism and dysphagia with a variable time delay (up to 10 days). No serious adverse effects occurred.Conclusions: The vast majority of late‐stage PD patients (92%) show a meaningful response to STN‐DBS. Effects of stimulation may take days to disappear after its discontinuation. We present a safe and effective decisional algorithm that could guide physicians and caregivers in making challenging therapeutic decisions in late‐stage PD. © 2020 International Parkinson and Movement Disorder Society
- 1 July 2019
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 64, 242-248
Is lowering stimulation frequency a feasible option for subthalamic deep brain stimulation in Parkinson's disease patients with dysarthria?
- 1 July 2019
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 64, 242-248
Is lowering stimulation frequency a feasible option for subthalamic deep brain stimulation in Parkinson's disease patients with dysarthria?
- 1 July 2019
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 64, 8-19
Genetic background and outcome of Deep Brain Stimulation in Parkinson's disease
- 1 July 2019
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 64, 8-19
Genetic background and outcome of Deep Brain Stimulation in Parkinson's disease
- Open Access
- 1 April 2014
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 20 (4) , 376-381
Long-term outcome of subthalamic nucleus DBS in Parkinson's disease: From the advanced phase towards the late stage of the disease?
- 1 April 2014
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 20 (4) , 376-381
Open AccessLong-term outcome of subthalamic nucleus DBS in Parkinson's disease: From the advanced phase towards the late stage of the disease?